The significant improvement in ovarian PCOS syndrome using hydralazine and alendronate aromatase inhibitor FDA-approved drugs in Wistar rat models
Open Access
- 29 March 2024
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 174, 116504
Abstract
No abstract availableKeywords
Funding Information
- Islamic Azad University (IR.IAU.Shiraz.REC.1401.006)
This publication has 33 references indexed in Scilit:
- Promising drug candidates for the treatment of polycystic ovary syndrome (PCOS) as alternatives to the classical medication metforminEuropean Journal of Pharmacology, 2023
- Drug Repurposing: a Shortcut to New Biological EntitiesPharmaceutical Chemistry Journal, 2022
- Immune regulation in polycystic ovary syndromeClinica Chimica Acta, 2022
- Hydralazine attenuates renal inflammation in diabetic rats with ischemia/reperfusion acute kidney injuryEuropean Journal of Pharmacology, 2021
- The effect of dapsone in testosterone enanthate-induced polycystic ovary syndrome in ratThe Journal of Steroid Biochemistry and Molecular Biology, 2021
- Taurine improves follicular survival and function of mice ovarian grafts through increasing CD31 and GDF9 expression and reducing oxidative stress and apoptosisEuropean Journal of Pharmacology, 2021
- Beneficial effects of minocycline on the ovary of polycystic ovary syndrome mouse model: Molecular docking analysis and evaluation of TNF-α, TNFR2, TLR-4 gene expressionJournal of Reproductive Immunology, 2021
- Cardioprotection of hydralazine against myocardial ischemia/reperfusion injury in ratsEuropean Journal of Pharmacology, 2020
- Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian diseaseArchives of Medical Research, 2004
- Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and manNaunyn-Schmiedeberg's Archives of Pharmacology, 1984